UK agency backs cancer drug after Sanofi cuts price

Britain’s healthcare cost watchdog NICE said on Friday it had changed its mind and decided to recommend Sanofi’s prostate cancer drug Jevtana after the French company agreed to a further discount.

The NationalInstitute for Health and Care Excellence (NICE) said the improved discount was “an excellent example of how pharma companies can work with us to ensure that patients have access to all of their treatment options”.

NICE, which has taken a firm stance on the issue of the cost-effectiveness of costly new medicines, did not give details of the latest price reduction. (Reporting by Ben Hirschler; editing by David Clarke)


Source: ETHealthworld

Date: 22nd April, 2016


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s